TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

Similar documents
TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

TDM of Aminoglycoside Antibiotics

PHA Case Studies V (Answers)

TDM. Measurement techniques used to determine cyclosporine level include:

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Name: UFID: PHA Exam 2. Spring 2013

PHARMACOKINETICS SMALL GROUP II:

Carbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8

Case Study 2 Answers Spring 2006

PHA 5128 Spring 2000 Final Exam

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

Basic Concepts of TDM

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA 5128 Spring 2009 First Exam (Version B)

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Career Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

TDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

Multiple IV Bolus Dose Administration

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

SHC Vancomycin Dosing Guide

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

PHA5128 Dose Optimization II Case Study 3 Spring 2013

A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

Selected Clinical Calculations Chapter 10. Heparin-Dosing calculations

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA5128 Dose Optimization II Case Study I Spring 2013

Pharmacokinetics Overview

Comparative Study of Different Digoxin Treatment Regimens in Egyptian Hospitals. For Partial Fulfillment of Master Degree in Pharmaceutical Sciences

(Max 2 g) = to nearest 250 mg

SYNOPSIS. The study results and synopsis are supplied for informational purposes only.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:

Adult Institutional Pharmacokinetics Protocol

Clinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Public Assessment Report. EU worksharing project paediatric data. Valcyte. Valganciclovir

Doses Target Concentration Intervention

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Carboplatin Time to Drop the Curtain on the Dosing Debate

Learning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol

DIRECT ORAL ANTICOAGULANTS

ECN Protocol Book. Generic Chemotherapy Protocol Guidelines. ECN_Protocol_Book_generic chemotherapy protocol guidelines guidelines_1

BIOPHARMACEUTICS and CLINICAL PHARMACY

A REVIEW ON DOSAGE REGIMEN

Comparing Methods for Once Daily Tobramycin Exposure Predictions in Children with Cystic Fibrosis

Physical and Sensory Changes in the Older Adult: Considerations for Medication Management

PHA Final Exam Fall 2001

NOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Vancomycin dosing in morbidly obese patients

Section 5.2: Pharmacokinetic properties

USES OF PHARMACOKINETICS

PAGE Meeting 2003 Verona, Italy

Southern Trust Anticoagulant Team

2017/3/7. Evaluation of GFR. Chronic Kidney Disease (CKD) Serum creatinine(scr) Learning Objectives

Myrna Y. Munar, Pharm.D., BCPS

Assessing Renal Function: What you Didn t Know You Didn t Know

VANCOMYCIN DOSING AND MONITORING GUIDELINES

WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT

Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations

CASUISTIEK: DOACS. Kop 1/02/2018. Voet 1 INLEIDING INLEIDING. Klassieke OAC. DOACs CORRECT DOSING. Prof. Stephane Steurbaut, PharmD, PhD

PHARMACOKINETICS SMALL GROUP I:

AMINOGLYCOSIDES TDM D O N E B Y

Egfr non african american vs african american

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

These are guidelines only and can be deviated from if it is thought to be in the patient s best interest.

What s new with DOACs? Defining place in therapy for edoxaban &

THE AMINOGLYCOSIDE ANTIBIOTICS

John E. Murphy, PharmD, FASHP, FCCP

PHA Final Exam Fall 2006

Drug dosing in Extremes of Weight

DIGOXIN COMPLIANCE: A PHARMACOKINETIC QUANTIFICATION

Pharmacy Math Skills Self-Assessment for Incoming P1 Students (Please allow 50 minutes and no calculators)

Cystatin C: A New Approach to Improve Medication Dosing

Pharmacokinetic Calculations

Pharmacy Math Skills Self-Assessment for Incoming P1 Students (Please allow 50 minutes and no calculators) Answer Keys

Drug Disposition in Obesity & Protein-Calorie Malnutrition

Dosing Information. The First & Only FDA-approved Spironolactone Oral Suspension P HARM A. Exclusively from

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Target Concentration Intervention

Tamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali

Transcription:

TDM Lecture 8 5 th Stage TDM of Digoxin Use of Digoxin Serum Concentrations to Alter Dosages Linear Pharmacokinetics Method This method is used in steady-state condition. We compute the new dose of digoxin by using the following equation: D new / Css new = D old / Css old Or D new = (Css new / Css old) D old Note: we should know at first if the drug has been reached to the steady-state concentration or not. Example1 MJ is a 50-year-old, 0-kg (5 ft in) male with atrial fibrillation for less than 24 hours. His current serum creatinine is 0.9 mg/dl, and it has been stable over the last 5 days since admission. A Digoxin tablet dose of 250 μg/day was prescribed and expected to achieve steady-state serum concentration equal to 0.8 μg/l. After a week of treatment, a steady-state serum concentration was measured and was equal to 0.6 μg/l. Calculate a new digoxin tablet dose that will provide a steadystate serum concentration equal to 0.9 μg/l. 1

Answer 1 Check if the patient has been reached to the steady-state concentration or not: CrClest = CrClest = [ (140 - age) * body weight] 2 * serum creatinine (Scr) [ (140-50 y) * 0 Kg] 2 * 0.9 mg/dl CrClest = 9 ml/min - From the following table we will know if the patient has been reached to the steady-state or not: Creatinine clearance ml/min 0 20 30 40 50 60 0 80 90 0 Number of days before steady-state achieved 22 19 16 14 13 12 11 9 8 2

- From the previous table we conclude that this patient has reached to the steadystate concentration (because there is more than days of treatment). Note: This step can be omitted if you know that the patient has reached to steadystate. 2 Compute the new dose: D new = (Css new / Css old) D old D new = (0.9 μg/l / 0.6 μg/l) 250 μg/day D new = 35 μg/day Therefore, the new suggested dose is 35 μg/day to be started at the next scheduled dosing time. Example2 OI is a 65-year-old, 10-kg (5 ft 5 in) female with NYHA class III moderate heart failure. Her current serum creatinine is 4. mg/dl and is stable. A digoxin IV dose of 125 μg/day was prescribed and expected to achieve steady-state serum concentration equal to 1 μg/l. After 3 week of treatment, a steady-state serum concentration was measured and was equal to 2.5 μg/l. Calculate a new digoxin IV dose that will provide a steady-state serum concentration equal to 1.2 μg/l. 1 Check if the patient has been reached to the steady-state concentration or not: The patient is obese (her weight is 10 kg) IBW= 45.5 + (2.3 * 5) = 45.5 + 11.5 = 5 kg The Salazar and Corcoran equation can be used: CrCl = ( 146 - age ) [ ( 0.28 * BW ) + ( 9.4 * Ht2 ) ] 60 * SCr 3

CrCl = ( 146-65 y ) [ (0.28 * 10 kg) + (9.4 * {1.65m}2 ) ] 60 * 4. mg/dl CrCl = 22 ml/min - From the following table we will know if the patient has been reached to the steady-state or not: Creatinine clearance ml/min 0 20 30 40 50 60 0 80 90 0 Number of days before steady-state achieved 22 19 16 14 13 12 11 9 8 - From the previous table we conclude that this patient has reached to the steadystate concentration (because there is more than 16 days of treatment). 4

2 Compute the new dose: D new = (Css new / Css old) D old D new = (1.2 μg/l / 2.5 μg/l) 125 μg/day D new = 60 μg/day (round to lowest 0 or 125 μg) D new = 120 μg every other day (rounded to 125 μg every other day) Therefore, the new suggested dose is 125 μg every other day. A day should be skipped before next dose is given. Pharmacokinetic Parameter Method: In this method, we calculate patient specific drug clearance and employ it to design better therapeutic regimen. D/τ = (Css Cl) / F, this is maintenance dose equation and through rearrangement we can get the following: Cl = [F*(D/τ)]/Css Where Cl: digoxin clearance in L/d, F: bioavailability factor, D/τ: maintenance dose in µg/d and Css: steady state concentration in ng/ml or µg/ml. Example 1: OI is a 65-year-old, 10-kg (5 ft 5 in) female with NYHA class III heart failure. Her current serum creatinine is 4. mg/dl and is stable. A digoxin dose of 125 μg/d given as tablets was prescribed and expected to achieve steady-state concentrations equal to 1 ng/ml. After the 3 weeks of therapy, a steady-state digoxin concentration was measured and equalled 2.5 ng/ml. Calculate a new digoxin dose that would provide a steady state concentration of 1.2 ng/ml. Answer: 1. Estimate creatinine clearance. IBW= 45.5+ (2.3*5) = 5 kg, so the patient is obese and we should apply Salazar and Corcoran equation to estimate creatinine clearance. 5

Note: Foot = 30.48 cm Inch = 2.54 cm Ht= (5 ft*30.48 cm/ft)+(5in*2.54 cm/in) = 165.1 cm, so the height is 1.65 m. By applying the following table, we conclude that the serum concentration had reached to steady state level (because there is more than 16 days of treatment). Creatinine clearance ml/min 0 20 30 40 50 60 0 80 90 0 Number of days before steady-state achieved 22 19 16 14 13 12 11 9 8 6

2. Compute drug clearance. Cl = [F(D/τ)] / Css = [0.(125 μg/d)] / 2.5 μg/l = 35 L/d 3. Compute new dose to achieve desired serum concentration. D/τ = (Css Cl) / F = (1.2 μg/l 35 L/d) / 0. D/τ = 60 μg/d, or 120 μg every other day (rounded to 125 µg every other day).